Trial Search Results

Phase 2 Trial of Enzastaurin in Prostate Cancer in Patients Who Have Had Hormonal and Chemotherapy

The purpose is to see how quickly two different types of prostate cancer patients respond when taking enzastaurin.

Cohort 1 - asymptomatic patients with androgen-independent PSA-progressive disease with or without clinical or radiographic evidence of metastatic disease.

Cohort 2 - patients with androgen-independent metastatic prostate cancer (documented bone or soft tissue metastases) with rising PSA, clinical, radiographic disease progression following one prior docetaxel-based regimen

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eli Lilly and Company

Stanford Investigator(s):


  • Drug: enzastaurin


Phase 2


Inclusion Criteria:

   - You are expected to be alive in the 12 weeks.

   - You are at least 18 years old.

   - You live close enough to the doctor's office to attend all of your required visits.

   - You have not been treated with chemotherapy for your prostate cancer (cohort 1).

   - You have had one prior docetaxel-based chemotherapy regimen (cohort 2).

   - You have evidence of metastatic prostate cancer with bone or soft tissue disease
   (cohort 2).

   - Your organs must be functioning properly.

Exclusion Criteria:

   - You are unable to swallow pills.

   - You have another illness besides your prostate cancer.

   - You have taken another experimental drug within the last 30 days.

   - You have a serious heart condition.

   - You are receiving another anti-cancer therapy.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
Not Recruiting